LUNGGuard® Used in Record Cross-Country Donor Lung Transplant Case Reports Paragonix Technologies

Device enables donor lungs to safely travel unprecedented distance of 4,788 Miles with a total ischemic time of over 13 hours

Paragonix LUNGGuard® System: Paragonix Technologies announces a milestone achievement as the device safely completed a record distance for donor lung transport from Alaska to North Carolina.

The longest case in terms of distance and total ischemic time for the LUNGguard Donor Lung Preservation system was completed by Duke University Hospital, one of the largest organ transplant centers in the world.

In the same transplant event, the Paragonix SherpaPak® Cardiac Transport System transported the heart from the same donor in Alaska to a patient in Washington State, with a total ischemic time of over 7 hours and a distance of 1,579 miles. In total, Paragonix Technologies enabled the successful transport of two organs from one donor through a process spanning five flights and 31 hours, resulting in two lives saved by multiple transplant centers across the US.

Four Transplant Centers across the U.S. worked together to make this monumental transplant event happen, including Duke University Hospital, which had a patient in need of a lung transplant. When Duke University Hospital found a donor match in Alaska for its patient, it faced challenges with distance that traditionally would be a high-risk transport due to complications typically associated long ischemic times for organs.

Duke University Hospital contacted Paragonix Technologies requesting a LUNGguard system for use in a long-distance lung transplant case. As the donor was located in Alaska, there was not enough time for the Duke University surgeon team to travel with the system to procure the organ themselves.  As a result of this unique situation, Duke utilized a procurement surgeon from a prominent West Coast transplant center, and the Paragonix team worked overnight to transport the LUNGguard Donor Lung Preservation System to that team in time for their flight to Alaska.

“While we consider many factors in selecting a donor, distance is a significant risk factor to moving forward. Transplant centers around the country are seeking ways to overcome the challenges associated with safely transporting organs further and new technologies show promise,” said Dr. John C. Haney, Assistant Professor of Surgery at Duke University

“We are committed to mitigating as much risk as we can in the high-stakes environment of transplantation. This case represents a great example of the possibilities afforded by enabling transplant teams to safely go farther to procure these much need donor organs.” said Lisa Anderson, Ph.D., Founder and CEO of Paragonix Technologies.

Both the Paragonix LUNGGuard System and the SherpaPak Cardiac Transportation System (CTS) provide a sterile and temperature-controlled environment for organs traveling between operating rooms and serve as an alternative to traditional ice transportation. The cooling technology employed by Paragonix Organ Preservation systems ensure thermal protection for up to 40 hours, while providing a rigid and protective structure for physical safety. The devices work with a state-of-the-art app that connect to the Paragonix devices via Bluetooth for on-the-go monitoring, vital for long-distance travel.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.